Traber Ghislaine L, Pangalu Athina, Neumann Manuela, Costa Joao, Weller Michael, Huna-Baron Ruth, Landau Klara
Department of Ophthalmology, University Hospital Zurich, Frauenklinikstrasse 24, CH-8091, Zurich, Switzerland,
Graefes Arch Clin Exp Ophthalmol. 2015 Jul;253(7):1187-94. doi: 10.1007/s00417-015-3045-8. Epub 2015 May 26.
Malignant optic glioma of adulthood is a rare, invasive neoplasm of the anterior visual pathway with 66 cases reported in the literature. It presents as anaplastic astrocytoma (WHO grade III) or glioblastoma (WHO grade IV). The present case series covers the spectrum of disease manifestations, discusses neuroradiological findings, and reviews the current literature.
Retrospective case series of five patients from three tertiary referral centers and literature review.
Visual loss with or without pain was the presenting symptom in all patients (two women, three men). Two patients were initially misdiagnosed as optic neuritis, and one patient as atypical non-arteritic anterior ischemic optic neuropathy (NAION). A neoplastic disease was suspected in the two remaining patients. MRI features were iso- to hypointensity on T1-weighted native images, contrast enhancement, and hyperintensity on T2-weighted images. Biopsy was generally diagnostic; however, one patient required two biopsies for diagnosis. The series includes an exceptional case of intraocular tumor extension and vitreous spread. The disease was lethal within one to two years in all patients.
Malignant optic glioma is a diagnostic challenge and remains a devastating and lethal disease. Advances in the understanding of tumor biology have yet failed to translate into effective treatment regimens.
成人恶性视神经胶质瘤是一种罕见的、侵袭性的前视觉通路肿瘤,文献报道有66例。它表现为间变性星形细胞瘤(世界卫生组织III级)或胶质母细胞瘤(世界卫生组织IV级)。本病例系列涵盖了疾病表现的范围,讨论了神经影像学检查结果,并回顾了当前的文献。
来自三个三级转诊中心的五例患者的回顾性病例系列及文献综述。
所有患者(两名女性,三名男性)的首发症状均为视力丧失,伴有或不伴有疼痛。两名患者最初被误诊为视神经炎,一名患者被误诊为非典型非动脉性前部缺血性视神经病变(NAION)。其余两名患者被怀疑患有肿瘤性疾病。MRI特征为T1加权原始图像上等信号至低信号、对比增强以及T2加权图像上高信号。活检通常具有诊断性;然而,一名患者需要两次活检才能确诊。该系列包括一例罕见的眼内肿瘤扩展和玻璃体播散病例。所有患者在一到两年内死亡。
恶性视神经胶质瘤是一项诊断挑战,仍然是一种具有毁灭性和致命性的疾病。对肿瘤生物学的理解进展尚未转化为有效的治疗方案。